Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy

Research output: Contribution to journalJournal articlepeer-review

Standard

Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. / Bohr, Adam; Nascimento, Thais Leite; Harmankaya, Necati; Weisser, Johan Juhl; Wang, Yingya; Grohganz, Holger; Rades, Thomas; Löbmann, Korbinian.

In: Molecules, Vol. 24, No. 2, 266, 2019.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Bohr, A, Nascimento, TL, Harmankaya, N, Weisser, JJ, Wang, Y, Grohganz, H, Rades, T & Löbmann, K 2019, 'Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy', Molecules, vol. 24, no. 2, 266. https://doi.org/10.3390/molecules24020266

APA

Bohr, A., Nascimento, T. L., Harmankaya, N., Weisser, J. J., Wang, Y., Grohganz, H., Rades, T., & Löbmann, K. (2019). Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules, 24(2), [266]. https://doi.org/10.3390/molecules24020266

Vancouver

Bohr A, Nascimento TL, Harmankaya N, Weisser JJ, Wang Y, Grohganz H et al. Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules. 2019;24(2). 266. https://doi.org/10.3390/molecules24020266

Author

Bohr, Adam ; Nascimento, Thais Leite ; Harmankaya, Necati ; Weisser, Johan Juhl ; Wang, Yingya ; Grohganz, Holger ; Rades, Thomas ; Löbmann, Korbinian. / Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. In: Molecules. 2019 ; Vol. 24, No. 2.

Bibtex

@article{5533bc5fd9294ce296daf23adc46cbec,
title = "Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy",
author = "Adam Bohr and Nascimento, {Thais Leite} and Necati Harmankaya and Weisser, {Johan Juhl} and Yingya Wang and Holger Grohganz and Thomas Rades and Korbinian L{\"o}bmann",
year = "2019",
doi = "10.3390/molecules24020266",
language = "English",
volume = "24",
journal = "Molecules",
issn = "1420-3049",
publisher = "M D P I AG",
number = "2",

}

RIS

TY - JOUR

T1 - Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy

AU - Bohr, Adam

AU - Nascimento, Thais Leite

AU - Harmankaya, Necati

AU - Weisser, Johan Juhl

AU - Wang, Yingya

AU - Grohganz, Holger

AU - Rades, Thomas

AU - Löbmann, Korbinian

PY - 2019

Y1 - 2019

U2 - 10.3390/molecules24020266

DO - 10.3390/molecules24020266

M3 - Journal article

C2 - 30642009

VL - 24

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 2

M1 - 266

ER -

ID: 211863219